These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
310 related articles for article (PubMed ID: 12411786)
21. Increasing the number of diagnostic mutations in malignant hyperthermia. Levano S; Vukcevic M; Singer M; Matter A; Treves S; Urwyler A; Girard T Hum Mutat; 2009 Apr; 30(4):590-8. PubMed ID: 19191329 [TBL] [Abstract][Full Text] [Related]
22. [In vitro contracture test and gene typing in diagnosing malignant hyperthermia. Each as an appropriate complement to the other method]. Rüffert H; Olthoff D; Deutrich C; Thamm B; Froster U Anaesthesist; 2000 Feb; 49(2):113-20. PubMed ID: 10756965 [TBL] [Abstract][Full Text] [Related]
23. A novel ryanodine receptor mutation and genotype-phenotype correlation in a large malignant hyperthermia New Zealand Maori pedigree. Brown RL; Pollock AN; Couchman KG; Hodges M; Hutchinson DO; Waaka R; Lynch P; McCarthy TV; Stowell KM Hum Mol Genet; 2000 Jun; 9(10):1515-24. PubMed ID: 10888602 [TBL] [Abstract][Full Text] [Related]
24. Caffeine and halothane sensitivity of intracellular Ca2+ release is altered by 15 calcium release channel (ryanodine receptor) mutations associated with malignant hyperthermia and/or central core disease. Tong J; Oyamada H; Demaurex N; Grinstein S; McCarthy TV; MacLennan DH J Biol Chem; 1997 Oct; 272(42):26332-9. PubMed ID: 9334205 [TBL] [Abstract][Full Text] [Related]
26. Effect of Norepinephrine on Intracellular Ca Perry SM; Muldoon S; Michaelson LP; Bunger R; Kasper CE AANA J; 2018 Oct; 86(5):383-392. PubMed ID: 31584408 [TBL] [Abstract][Full Text] [Related]
27. Ryanodine receptor mutations in malignant hyperthermia and central core disease. McCarthy TV; Quane KA; Lynch PJ Hum Mutat; 2000; 15(5):410-7. PubMed ID: 10790202 [TBL] [Abstract][Full Text] [Related]
28. C1840-T mutation in the human skeletal muscle ryanodine receptor gene: frequency in northern German families susceptible to malignant hyperthermia and the relationship to in vitro contracture response. Steinfath M; Singh S; Scholz J; Becker K; Lenzen C; Wappler F; Köchling A; Roewer N; Schulte am Esch J J Mol Med (Berl); 1995 Jan; 73(1):35-40. PubMed ID: 7633940 [TBL] [Abstract][Full Text] [Related]
29. Functional defects in six ryanodine receptor isoform-1 (RyR1) mutations associated with malignant hyperthermia and their impact on skeletal excitation-contraction coupling. Yang T; Ta TA; Pessah IN; Allen PD J Biol Chem; 2003 Jul; 278(28):25722-30. PubMed ID: 12732639 [TBL] [Abstract][Full Text] [Related]
30. Functional characterization of malignant hyperthermia-associated RyR1 mutations in exon 44, using the human myotube model. Wehner M; Rueffert H; Koenig F; Olthoff D Neuromuscul Disord; 2004 Jul; 14(7):429-37. PubMed ID: 15210166 [TBL] [Abstract][Full Text] [Related]
31. Mutations to Gly2370, Gly2373 or Gly2375 in malignant hyperthermia domain 2 decrease caffeine and cresol sensitivity of the rabbit skeletal-muscle Ca2+-release channel (ryanodine receptor isoform 1). Du GG; Oyamada H; Khanna VK; MacLennan DH Biochem J; 2001 Nov; 360(Pt 1):97-105. PubMed ID: 11695996 [TBL] [Abstract][Full Text] [Related]
32. 4-Chloro-m-cresol: a specific tool to distinguish between malignant hyperthermia-susceptible and normal muscle. Herrmann-Frank A; Richter M; Lehmann-Horn F Biochem Pharmacol; 1996 Jul; 52(1):149-55. PubMed ID: 8678899 [TBL] [Abstract][Full Text] [Related]
33. Characterization of ryanodine receptor-mediated calcium release in human B cells: relevance to diagnostic testing for malignant hyperthermia. McKinney LC; Butler T; Mullen SP; Klein MG Anesthesiology; 2006 Jun; 104(6):1191-201. PubMed ID: 16732090 [TBL] [Abstract][Full Text] [Related]
34. Functional characterisation of the R2452W ryanodine receptor variant associated with malignant hyperthermia susceptibility. Roesl C; Sato K; Schiemann A; Pollock N; Stowell KM Cell Calcium; 2014 Sep; 56(3):195-201. PubMed ID: 25086907 [TBL] [Abstract][Full Text] [Related]
35. Detection of a novel ryanodine receptor subtype 1 mutation (R328W) in a malignant hyperthermia family by sequencing of a leukocyte transcript. Loke JC; Kraev N; Sharma P; Du G; Patel L; Kraev A; MacLennan DH Anesthesiology; 2003 Aug; 99(2):297-302. PubMed ID: 12883402 [TBL] [Abstract][Full Text] [Related]
36. Sources of variability in halothane and caffeine contracture tests for susceptibility to malignant hyperthermia. Ording H; Bendixen D Eur J Anaesthesiol; 1992 Sep; 9(5):367-76. PubMed ID: 1396623 [TBL] [Abstract][Full Text] [Related]
37. Calcium release from sarcoplasmic reticulum is facilitated in human myotubes derived from carriers of the ryanodine receptor type 1 mutations Ile2182Phe and Gly2375Ala. Wehner M; Rueffert H; Koenig F; Olthoff D Genet Test; 2003; 7(3):203-11. PubMed ID: 14641996 [TBL] [Abstract][Full Text] [Related]
38. Inositol 1,4,5-trisphosphate synthesis in mononuclear white blood cells of malignant hyperthermia-susceptible and normal human beings, following in vitro exposure to halothane, caffeine and ryanodine. Martens U; Krause T; Scholz J; Wappler F; Steinrücke K; am Esch JS Eur J Anaesthesiol; 2000 Jun; 17(6):364-72. PubMed ID: 10928436 [TBL] [Abstract][Full Text] [Related]
39. Enhanced response to caffeine and 4-chloro-m-cresol in malignant hyperthermia-susceptible muscle is related in part to chronically elevated resting [Ca2+]i. López JR; Linares N; Pessah IN; Allen PD Am J Physiol Cell Physiol; 2005 Mar; 288(3):C606-12. PubMed ID: 15537710 [TBL] [Abstract][Full Text] [Related]
40. In vitro diagnosis of malignant hyperthermia susceptibility with ryanodine-induced contractures in human skeletal muscles. Wappler F; Roewer N; Köchling A; Scholz J; Steinfath M; Schulte am Esch J Anesth Analg; 1996 Jun; 82(6):1230-6. PubMed ID: 8638796 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]